September 1, 2010
Financing, clinical data, and strategic collaboration position company for continued strong growth
San Diego, CA — Accumetrics, Inc., a privately-held developer and marketer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, announced today that it has completed its capital financing efforts, the first round of which was announced in the Fall of 2009. Read More…
August 30, 2010
Strong Investor Syndicate to Fund Otonomy to Become Leading Company in the
Development of Locally Delivered Therapeutics for Ear Disorders
SAN DIEGO, CA — Otonomy, Inc. announced today that it has closed a $38.5 million Series B financing co-led by Novo Ventures and RiverVest Venture Partners Read More…
July 13, 2010
Collaboration seeks to increase awareness about the importance of measuring patients’ platelet response to antiplatelet therapy
San Diego, CA, Parsippany, NJ and Indianapolis, IN — Accumetrics, Inc., Daiichi Sankyo, Inc, and Eli Lilly and Company announced today that the companies have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of platelet function testing. Read More…
June 25, 2010
- Deal to Broaden Gilead’s Research Expertise into Kinase Biology and Chemistry -
Foster City, CA and Branford, CT – Gilead Sciences, Inc. (Nasdaq: GILD) and CGI Pharmaceuticals, Inc., a privately-held, development-stage pharmaceutical company focused on small molecule chemistry and kinase biology, today announced the signing of a definitive agreement pursuant to which Gilead will acquire CGI. Read More…
